Patheon to Host Strategy Seminar for Emerging Companies

Industry-leading experts will discuss key strategies for early product development at a seminar this month hosted by  Patheon®, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The event “API Supply: Key Strategies for Creating Value in Early-Stage Development,” which looks to address challenges in API development and drug formulation for emerging companies will be held Thursday, March 19, at the Embassy Suites Airport-Waterfront in San Francisco from 11:30 a.m. to 3:30 p.m.

Experts will provide attendees with key strategies for API development. Presentations include:

  • Rapid Path to First-time-in-Humans: An Example of Expedited Chemical Development” by Sriram Naganathan, Ph.D., senior director, chemical development at Dermira, presenting an example of expedited chemical development of a kinase inhibitor toward enabling first-in-human clinical studies.
  • “API Continuous Process Considerations” by Peter Poechlauer, Ph.D., innovation manager, Patheon, highlighting scalability as a key factor for product development.
  • “How IP Decisions Can Add Value” by Bernie Brown, Ph.D., patent attorney, Womble Carlyle Sandridge & Rice, sharing insights on how to add product value based on key intellectual property decisions, and discuss the importance of early-stage patents, as well as tips on developing an IP strategy that provides commercially relevant coverage and value throughout the drug life cycle.

For more information and to register, please visit

Patheon Media Relations

Tel: +1 (919) 210-0986

Email: or

About Patheon®

Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit